RA Capital Management is a Boston-based investment firm specializing in healthcare, life sciences, and planetary health. It pursues evidence-based, science-led investing through its internal TechAtlas research engine and supports portfolio companies via its Raven healthcare incubator. The firm engages across stages from seed funding to IPOs and follow-on financings, focusing on drugs, medical devices, diagnostics, and other biomedical innovations, with a regional emphasis on the United States and Europe.

MassVentures is a Massachusetts-based venture capital firm focused on seed and early-stage investments that advance high-growth startups from concept to commercialization within the state’s innovation economy. Established in 1978 as a quasi-public entity by the Massachusetts Legislature and governed by an independent board, the firm funds ventures in deep tech and related sectors, including quantum computing, clean energy, biotech, artificial intelligence, advanced materials, manufacturing, and robotics. It has backed hundreds of companies and oversees more than $4 billion in follow-on capital, reflecting a durable track record of helping startups attract additional funding and scale. Beyond capital, MassVentures provides non-dilutive grants, commercialization support, mentorship, and strategic guidance through programs such as MV Capital and MV Accelerate, all aimed at building inclusive, connected ventures that leverage Massachusetts’ innovation ecosystem.

Atlas Venture is a Cambridge, Massachusetts-based venture capital firm that specializes in early-stage investments in biotechnology and life sciences, with additional focus on technology companies. It partners with life science entrepreneurs to translate scientific discoveries into medicines and related diagnostics, often leading seed or Series A rounds and providing strategic guidance and board involvement. Founded in 1980, Atlas Venture has organized multiple funds and operates with dedicated Life Sciences and Technology teams to manage portfolio companies across the United States and Europe. Its portfolio emphasizes biopharmaceuticals, therapeutics, and medical technologies, along with software and data-driven technologies that support life science commercialization.

Morningside Group is a Boston-area venture capital firm founded in 1986 as a family office for the Chan family. It makes long-term investments in companies applying novel science and technology, with expertise in life sciences, digital health, AI, materials, and technology, and a commitment to ethical business practices. The firm supports education, research, and healthcare through charitable initiatives with partners including Harvard T.H. Chan School of Public Health, UMass Chan Medical School, and MIT Morningside Academy for Design.

Alumni Ventures is a venture capital firm that provides accredited investors access to venture-stage and late-stage private market investments. It offers funds, syndicates, investing clubs, and co-investment opportunities with established venture capital firms, and it provides venture investing education through AV Academy along with resources for startup founders.

General Catalyst is a venture capital firm founded in 2000 and based in Cambridge, Massachusetts, with six global offices. It invests in seed to growth-stage companies across sectors including consumer, enterprise software, fintech, crypto, healthcare, and artificial intelligence, providing capital and strategic guidance to help founders scale. The firm emphasizes mentorship and hands-on support to portfolio companies and aims to accelerate ideas, careers, and ventures. General Catalyst manages a large pool of capital and operates multiple funds, funding minority and majority stakes to help companies achieve scale.

OrbiMed is a global healthcare investment firm based in New York, founded in 1989. It manages capital across public and private markets, including private equity, venture and growth investments, and private credit, with structured debt and royalty arrangements to support owners of intellectual property and diagnostics. The firm focuses on biopharmaceuticals, life sciences, medical devices, diagnostics, health IT, and healthcare services, investing from startups to multinational companies. With a worldwide team and offices in multiple regions, OrbiMed provides financing and strategic resources to advance therapies and healthcare innovations, aiming to improve patient outcomes across global markets.

Flagship Pioneering is a Cambridge, Massachusetts-based venture creation company that conceives, builds, and resources first-in-category ventures aimed at transforming human health, biotechnology, and sustainability. Through an integrated approach that combines scientific discovery with entrepreneurial capital, it develops ideas from inception through company creation, supporting portfolio companies such as Moderna, Tessera Therapeutics, Generate Biomedicines, and Quotient Therapeutics. It pursues ambitious programs in biology, medicine, energy, and related fields, frequently collaborating with industry partners and institutions to accelerate discovery and development. The firm emphasizes fearless exploration and an evolutionary methodology to translate scientific breakthroughs into durable companies and impactful solutions for people and the planet.

ARCH Venture Partners is a venture capital firm founded in 1986 and based in Chicago, Illinois, with additional operations in Seattle. The firm focuses on science-based companies, prioritizing life sciences and related technologies, and aims to translate academic and national lab innovations into commercially viable products. ARCH emphasizes a true partnership approach, providing capital alongside strategic guidance, expertise, and a broad professional network to founders. It has supported numerous companies across early to growth stages and is known for backing translational efforts that bring breakthrough discoveries to market, leveraging collaborations with researchers and entrepreneurs to accelerate development of disruptive technologies on a national and international scale.

Mission BioCapital is a life science venture capital firm that backs early-stage biotechnology and life sciences companies. With leadership that has a long history of founding and supporting dozens of startups, the firm operates from Cambridge, Massachusetts and San Francisco, California, leveraging a network of researchers and venture capital partners. It provides mentorship, collaboration, and hands-on support from concept through clinical trials, including access to shared laboratory space through its Platinum Program, which offers up to $500,000 in funding, a lab bench, and related services for promising startups. The firm focuses on accelerating scientific solutions and actively participates in portfolio company growth across therapeutic areas, backing companies through multiple funds.

Invus is a long-standing private investment firm founded in 1985 that partners with entrepreneurs and owner-managers to drive transformational growth. It emphasizes long-term alignment of incentives and provides capital and strategic guidance to help companies scale and innovate. With offices in New York, London, Paris and Hong Kong, Invus manages a substantial evergreen capital base that affords flexible engagement across private equity, co-investments, and related opportunities. The firm backs market-leading management teams across sectors such as consumer products, technology, life sciences, software, agtech, industrials and services, often taking both lead and co-investment roles. Through affiliated advisory and investment entities, Invus combines financial backing with strategic counsel to support enduring value creation over time.

Founder Collective is a seed-stage venture capital firm focused on technology startups. Founded in 2009 by entrepreneurs who have built and exited technology companies, it emphasizes founder-aligned partnerships and capital efficiency, aiming to minimize dilution while supporting portfolio companies from idea to IPO. The firm takes a technology-centric, stage-agnostic approach within seed and early stages and makes investments across the United States and worldwide. Headquartered in Cambridge, Massachusetts, with an office in New York City, Founder Collective leverages the experience of its founders to provide hands-on guidance to portfolio companies. It is built by a collection of successful entrepreneurs and concentrates on backing ambitious teams with potential to reshape industries, prioritizing authenticity, long-term value creation, and close collaboration with founders.

New Enterprise Associates is a global venture capital firm founded in 1977 and based in Menlo Park, California. It provides capital and operational support to companies across development stages, from seed to IPO, with a focus on technology and healthcare sectors. The firm collaborates with founders to address technical challenges, offering domain expertise to assist product development and market expansion. NEA invests across the United States, Asia and Brazil, and its portfolio includes software, consumer technology, medical devices, life sciences, healthcare information technology, and energy technology companies. With a long track record of helping entrepreneurs achieve growth, NEA emphasizes enduring partnerships and strategic guidance alongside funding to build transformational businesses through multiple stages of a company lifecycle.

Third Rock Ventures is a Boston-based venture capital firm founded in 2007 that invests in life sciences and healthcare companies, including biotechnology, medical devices, diagnostics, therapeutics, and related information technology. The firm targets early-stage and growth opportunities, frequently leads rounds, and takes an active role in portfolio companies, often pursuing strategic collaborations with larger pharmaceutical and biotechnology partners to advance medicines and technologies. Its focus spans oncology, autoimmune diseases, genetic disorders, and other therapeutic areas with the aim of improving patient outcomes through innovative drug development and diagnostics.

Accomplice is a seed-led venture capital firm based in Cambridge, Massachusetts, that backs early-stage technology startups. The firm focuses on cybersecurity, esports, data analytics, SMB-class software, emerging hardware platforms, and marketplaces, and supports founders through a community-driven model that leverages platforms and networks to fund and accelerate ventures. Originating as Atlas Venture, the technology group was renamed Accomplice in 2014 as part of a strategic split between technology and life sciences franchises. Accomplice maintains a strong presence in the New England startup ecosystem and invests across the United States, Canada, and Europe.

SOSV is a global venture capital firm focused on early-stage deep-tech and cross-border software companies, investing primarily from pre-seed through growth stages. It accelerates product development, regulatory progress, fundraising, and commercial strategy by providing founders access to purpose-built labs, engineering spaces, and a broad physical and virtual infrastructure across multiple locations. The firm's program-driven approach combines selective funding with hands-on support, mentorship, and a wide network of co-investors and partners to help portfolio companies scale. SOSV operates a suite of specialized facilities for deep-tech founders, including incubation programs that connect startups with customers, researchers, and investors, and it emphasizes long-term relationships through ongoing operational and strategic assistance. While active globally, it maintains strong ties to Asia-focused cross-border markets and supports a diverse portfolio spanning bio-tech, hardware, robotics, software, and related fields.

Casdin Capital is a New York-based venture capital and investment firm focused on the life sciences and healthcare sectors. Founded in 2012 by Eli Casdin, the firm backs companies across genomic research, molecular medicine, precision medicine, diagnostics, synthetic biology, oncology, digital health, and related technologies. It pursues a data-driven, long-term investment approach and seeks to form strong partnerships with portfolio companies to advance scientific innovation and improve patient outcomes. The firm engages with ventures at various stages, from early- to late-stage private companies, emphasizing opportunities at the intersection of biology and technology. Through its activity in life sciences and healthcare, Casdin Capital positions itself as a partner to founders pursuing breakthroughs in genomics, molecular medicine, and AI-enabled healthcare platforms.

Hyperplane Venture Capital is a Boston-based early-stage venture capital firm that backs technology companies, with a focus on machine intelligence, data, and related technologies. The firm invests in early-stage startups across sectors including artificial intelligence and machine learning, distributed systems, automation, cloud computing, ambient intelligence, robotics, virtual reality, and augmented reality, partnering with exceptional founders who leverage machine intelligence, sensor technology, and cloud computing to solve complex problems and create solutions at the intersection of perception, communication, intelligence, and insight. It was founded in 2015 by Vivjan Myrto, John Murphy, and Brendan Kohler.

Spark Capital is a venture capital firm founded in 2005 and based in San Francisco, with additional offices in Boston and New York. It invests across sectors including consumer, software, fintech, media, internet, education technology, and mobile, backing both early-stage and growth-stage startups. The firm is known for a founder-focused approach that emphasizes flexibility over rigid playbooks, supporting teams as they build and scale innovative products. Its portfolio includes high-profile companies such as Twitter, Discord, Oculus, Warby Parker, Niantic, and Tumblr, reflecting a history of backing companies at pivotal moments in technology and consumer markets.

.406 Ventures is a Boston-based early-stage venture capital firm that invests in enterprise information technology, cybersecurity, data and cloud, and technology-enabled software and services companies. Founded in 2005, the firm seeks to back B2B and healthcare-related technology sectors, including SaaS, AI, fintech, and digital health, often taking the lead as the first institutional investor in seed and de novo rounds. Investments typically range from $2 million to $5 million initially, with total commitments around $6 million to $10 million per company, and the firm aims to hold board seats as a lead investor. The team emphasizes hands-on involvement, leveraging practical industry experience and networks to help portfolio companies scale. It pursues opportunities across the United States, with emphasis on information technology security and infrastructure and other next-generation software and services.

Beacon Angels is a Boston-based angel investment group founded in 2006 that funds early-stage, high-growth companies in New England. The group typically invests in the range of tens of thousands to a few hundred thousand dollars per company and conducts regular screening of opportunities, with monthly meetings for accredited members and scheduled reviews of new ventures, aiming to grow portfolio value through shared capital and strategic relationships.

Deerfield Management is a healthcare-focused investment firm that advances human health by investing in both public and private healthcare companies and by supporting research and development initiatives. The firm targets a broad range of healthcare sectors, including biotechnology, pharmaceuticals, diagnostics, medical devices, digital health, and healthcare services. It seeks to create value through long-term capital deployment, collaboration with strategic partners, and its internal efforts to foster scientific research and drug discovery. In addition to investment activity, Deerfield operates philanthropic initiatives through the Deerfield Foundation that fund education, expanded healthcare access, and health-outcomes improvement.

TCG Crossover is a science-driven healthcare investment firm dedicated to advancing disruptive medicines and supporting companies that can improve patients' lives. It invests in both private and public companies led by entrepreneurs developing better treatment options, with teams in Palo Alto and New York City. The firm leverages scientific expertise to identify and back breakthrough pharmaceutical therapies and health technology opportunities, aiming to accelerate innovation in the pharmaceutical sector and to help management teams translate discovery into patient benefit.

Boston Seed Capital is a Boston-headquartered venture capital firm that focuses on seed and early-stage investments in internet-enabled and technology-driven companies across the United States. The firm backs startups in consumer, B2B software as a service, and related services sectors, including information technology, cybersecurity, e-commerce, big data, marketplaces, esports, artificial intelligence and machine learning. It maintains a presence in Wellesley Hills, Massachusetts, and supports founders from pre-seed to scale, leveraging the Boston innovation ecosystem to help accelerate growth.

Safar Partners is a Cambridge, Massachusetts based venture capital firm founded in 2018 that focuses on seed- to growth-stage technology startups in the United States, leveraging connections to leading universities such as MIT, Harvard, and the University of Rochester to source and support early-stage companies. It invests across sectors including cleantech, advanced materials, artificial intelligence and IT and robotics, and life sciences and medical devices, with a flexible investment approach designed to help companies grow from inception to global scale, and it emphasizes environmental, social, and governance considerations in its investment process to pursue sustainable innovation and strong financial returns.

Launchpad Venture Group is a Boston-based angel investment group that provides funding and strategic guidance to early-stage science and technology startups, primarily in New England. Established in 2001, it operates as a network of individual angel investors and has invested more than $125 million in over 150 startups. The group offers both financial capital and mentorship to help entrepreneurs build long-term value, positioning itself as a leading seed investor in the region across sectors including software, hardware, life sciences, and clean tech. It emphasizes active involvement, advisory support, and building lasting relationships with founders, and it is a member of the Angel Capital Association.

Northpond Ventures is a science-driven venture capital firm based in Bethesda, Maryland, with offices in San Francisco and Cambridge. It focuses on life sciences, digital health, health tech, and adjacent technology sectors, including diagnostics, therapeutics, artificial intelligence, and machine learning. The firm backs science-based companies across development stages, providing capital and strategic support to enable growth and commercial success.

Pillar VC is a Boston-based venture capital firm focused on seed and early-stage technology companies, including healthcare, biotechnology, artificial intelligence, and scientific discovery. The firm partners with technically driven founders from inception, applying a lab-to-launch playbook to turn research into market-leading companies. Its portfolio includes Abridge, Videa Health, PathAI, Neural Magic, Latent Labs, and Edison, among others, reflecting a commitment to healthcare outcomes, computing and enterprise intelligence, and innovative discovery approaches. Pillar VC backs more than 90 companies, with many originating from university research.

MPM BioImpact is a venture capital firm focused on building and funding biotechnology companies to transform patient outcomes by developing innovative medicines. Based in Boston, the firm brings more than three decades of experience in translating scientific research into clinical impact and pursues opportunities across the biotechnology, healthcare, and life sciences sectors in the United States. It supports the full drug development process, from discovery through clinical proof of concept and regulatory milestones, with emphasis on areas such as oncology, immunology, neuroscience, and mental health. MPM BioImpact combines deep scientific expertise with strategic leadership to help portfolio companies navigate development challenges and accelerate patient-ready therapies. The firm has backed notable companies across its focus areas, leveraging hands-on guidance and collaboration to translate science into meaningful medical advances.

CRV is a Palo Alto-based venture capital firm established in 1970 that invests in early-stage technology-driven startups, typically from seed to Series B. The firm adopts a hands-on, value-added approach, working closely with founders to guide product strategy, team building and go-to-market execution as companies scale. CRV funds a broad set of sectors including technology, consumer goods and services, healthcare and life sciences, with North American focus. It operates from offices in Cambridge, Massachusetts and Menlo Park, California, and is recognized as one of the longest-running and most established early-stage firms in the industry. Over its history CRV has backed numerous high-growth, category-defining companies and emphasizes a long-term partnership philosophy that pairs capital with strategic support to help portfolio founders reach significant milestones.

Prelude Ventures is a San Francisco-based venture capital firm that backs early-stage startups focused on mitigating climate change. Founded in 2013, the firm targets investments across built environment, carbon management, compute, energy, food and agriculture, manufacturing and industrials, and mobility, seeking to support category-defining companies and scalable climate solutions.

Tiger Global Management is a global investment firm founded in 2001 by Charles (Chase) Coleman. It invests in both private and public markets worldwide, with a focus on technology, internet, consumer, and financial services companies. The firm employs strategies across public equities, including growth and long/short approaches, and private investments across early to late stages, seeking high-quality growth opportunities throughout the lifecycle of portfolio companies. Its activities span globally, aiming to back innovative companies across diverse regions and industries. As a registered investment adviser in the United States, Tiger Global conducts its business through its own platform, dedicating capital to long-term partnerships with high-potential companies.

Khosla Ventures is a California-based venture capital firm founded in 2004 that backs technology-driven startups across multiple sectors, including artificial intelligence, healthcare, sustainability, digital health, and consumer technology. The firm provides capital and strategic guidance to companies at early and growth stages, with an emphasis on disruptive technologies and world-changing businesses. It operates a range of funds, including seed and later-stage vehicles, and maintains a broad investment thesis that covers AI, climate tech, energy efficiency, and other high-potential areas, primarily focused in the United States. The firm is known for working closely with entrepreneurs to build long-lasting companies.

E14 Fund is a venture capital firm based in Cambridge, Massachusetts, focused on early‑stage investments that originate from the Massachusetts Institute of Technology. The firm helps bring technologies out of the lab and into the real world by connecting founders with a network of investors, industry experts, and mentors to scale startups and secure subsequent rounds. It backs seed‑ to early‑stage companies across diverse sectors, including biotechnology, smart cities, consumer electronics, manufacturing, and other deep‑tech areas, with a focus on MIT‑origin ideas. The firm emphasizes diversity and inclusion, with half of its portfolio companies having a female founder and more than half led by founders from outside the United States.

G20 Ventures is a venture capital firm based in the Cambridge/Boston area of Massachusetts that invests in early‑stage enterprise software and infrastructure companies on the East Coast. Established in 2013, it targets Series A rounds with typical checks of 2 to 5 million and reserves capital for earlier or follow‑on investments to stay with portfolio companies. The firm prioritizes technology risk over market risk and seeks teams with a technologist and a business leader who deeply understands the buyer and go‑to‑market. A product in the market with some customer validation is preferred. G20 provides hands‑on support and builds a community of founders, operators, and investors to aid growth through strategic capital deployment, aiming for long‑term value creation and efficient capital utilization with minimal dilution as companies scale.

Sequoia Capital is a venture capital firm founded in 1972 and based in Menlo Park, California. It provides capital and strategic guidance to technology companies across seed, early and growth stages, helping startups develop products, scale operations, and expand into new markets. The firm emphasizes long-term partnerships, closely supporting leadership through multiple funding rounds and critical strategic initiatives as companies mature. Sequoia operates globally, with activity in the United States, China, India and Israel, among other regions.

EcoR1 Capital is a venture capital firm based in San Francisco that invests in early-stage biotechnology companies developing innovative therapeutics. It applies a scientific approach, leveraging advances in molecular biology to identify promising ventures and support their pursuit of new medicines. The firm emphasizes partnering with entrepreneurs dedicated to therapeutic innovation and provides strategic and scientific guidance to help translate breakthrough discoveries into treatments for patients.

Gutbrain Ventures is a Boston-based venture capital firm that invests primarily in enterprise software companies. It operates as an independent firm and is led by veteran investor Bob Davoli, whose approach combines deep market and technology understanding with a direct, supportive style and a long-term commitment to portfolio companies. The firm has a track record of backing ventures across diverse sectors and helping CEOs navigate growth and exits through strategic partnerships and operational insights.

Venrock is a venture capital firm founded in 1969 as the venture capital arm of the Rockefeller family. It concentrates on seed and first-round investments in technology and healthcare, with a broad remit across information technology, life sciences, media, energy, and emerging tech. The firm backs early- and growth-stage companies and has supported a number of notable portfolio companies, including Apple Computer, Intel, Illumina, Gilead Sciences, Endeca, Imperva, DoubleClick, Athenahealth, Centocor, Check Point Software, Nest, SlideShare, and Tudou. Venrock emphasizes partnering with entrepreneurs to build enduring companies and leverages its long history in technology and healthcare to help founders navigate growth, strategy, and complex markets.

CVP Management is a venture capital firm focused on early‑stage technology investments, including seed and early Series A rounds. It concentrates on information technology infrastructure with emphasis on software applications, internet, digital media, digital marketing, vertical SaaS, cloud, embedded software, mobile, and financial services technologies. The firm typically invests from $0.1 million to $1 million, and for seed and Series A rounds from $1 million to $3.5 million, in companies with an enterprise value around $5 million. It prefers to hold a seat on the portfolio company board and to invest in preferred stock. The firm funds companies located in the Northeast corridor, especially Boston, New York, and Toronto, and began operation on June 1, 1998, with headquarters in Cambridge, Massachusetts, and an additional office in Boston.

Samsara BioCapital is a venture capital firm based in Palo Alto, California, founded in 2016. The firm focuses on the healthcare sector, investing in biotechnology companies across the United States and serving as an investment adviser to support the development of transformative therapeutics. By combining scientists, clinicians, drug developers, and business leaders with extensive experience, Samsara BioCapital aims to accelerate the next generation of therapies through collaborative partnerships and strategic capital. The firm operates as a principal investor and provides guidance to entrepreneurs seeking to turn their ideas into successful biotech ventures.

Boxer Capital is a biotechnology investment firm that serves as the corporate venture capital arm of Tavistock Group. Based in San Diego, California, it invests in both public and private biotechnology and life sciences companies across the drug development lifecycle, with a focus on precision medicine and oncology. The firm emphasizes rigorous, science-driven due diligence spanning scientific, clinical, regulatory, and commercial aspects to identify promising opportunities. It supports portfolio companies through independent investment decisions grounded in thorough research and seeks to back innovative assets and companies across private and public markets.

Sigma Partners was a venture capital firm founded in 1984, based in Boston with additional offices in Menlo Park, California and San Ramon, California. It invested in early-stage companies across sectors including semiconductors, mobile computing, electronics, infrastructure, internet and software, and managed more than $2 billion in capital. The firm supported a wide range of startups and raised funds such as Sigma Partners 8. Over its history it focused on companies in the United States and Canada. The original firm has since split into two smaller investment firms: Sigma West, now Jackson Square Ventures, and Sigma Prime Ventures.

Right Side Capital Management is a San Francisco-based venture capital firm that employs a quantitative, data-driven approach to fund technology startups at the earliest stages. Founded in 2012, it concentrates on capital-efficient companies that are generating revenue and typically seeks rounds of 50,000 to 500,000 dollars, often outside the traditional SF Bay Area and NYC hubs. The firm targets pre-product-market fit ventures across the United States and Canada, making a high volume of investments—hundreds of portfolio companies and more than two thousand investments since inception—with a philosophy of rapid, transparent decision-making and broad post-investment engagement. Its team leverages extensive operational experience to provide hands-on mentorship in areas such as sales, marketing, fundraising, and operations, aiming to support startups through critical growth phases and facilitate later-stage partnerships. RSCM positions itself as an operating-style fund focused on supporting founders, not a standard VC, and emphasizes building a diverse, founder-focused community through events and guidance.

Boston Harbor Angels is a Boston-based group of seasoned business leaders that invests in high-growth, early-stage companies. Founded in 2004, the group provides capital and hands-on guidance, drawing on expertise in life sciences, information technology, consumer products, fintech, healthcare, and related sectors. They typically participate in rounds of about 250,000 to 1.5 million, funding a portion of the round and syndicating with other angel groups or venture funds. Companies backed are expected to be close to commercialization with a defensible competitive edge and strong capital efficiency, able to reach profitability with less than five million dollars of equity investment and to generate at least a tenfold return within five years. Investments are made by individuals rather than a pooled fund, though members collaborate on due diligence and may act as lead or follow-on investors, particularly in life sciences. The group operates a structured screening process and is guided by a managing director, with a track record of mentorship, networking, and support for portfolio companies.

Omega Funds is a Boston-based venture capital firm founded in 2004 that focuses on investing in life sciences and related technologies. The firm targets opportunities in healthcare and biotech, including digital health, immunology, rare diseases, precision medicine, oncology, cybersecurity, and software-as-a-service, with activity across North America and Western Europe. Omega Funds acts as a registered investment adviser, supporting early-stage and growth companies as they develop therapeutic and digital health solutions.

Longwood Fund is a Boston-based life science venture investment firm focused on identifying and supporting innovative technologies and the teams developing them to advance patient care. It funds and guides early-stage science through clinical development and commercialization, concentrating on healthcare, pharmaceutical, and biotechnology sectors. The firm leverages a broad network of industry experts to advise and accelerate the growth of its portfolio companies from discovery to market. Since its founding in 2010, Longwood has demonstrated a track record of translating scientific breakthroughs into tangible treatments, with several portfolio companies bringing products to market and multiple therapies advancing in late-stage development. The organization continues to seek opportunities in promising life science ventures and provides strategic support to teams throughout the development journey.

Refactor Capital is a California-based venture capital firm that specializes in seed-stage hard-tech investments. Based in Burlingame, it is led by Zal Bilimoria as a sole founder and concentrates on early-stage companies across the United States in areas such as bio, energy, earth systems, aerospace, manufacturing, and critical materials. The firm pursues real-world applications of technology and acts as a proactive partner to founders, typically making checks in the range of $1-2 million to support product development and market entry.

5AM Ventures is a San Francisco-based venture capital firm founded in 2002 that provides seed- and early-stage capital to life sciences companies. The firm focuses on biopharmaceuticals, medical devices and instruments, digital health, and related health technologies, with an emphasis on early-stage private therapeutics and other life science ventures in the United States. It supports early rounds such as Series A and collaborates with academics, researchers, and entrepreneurs to advance proof-of-concept data and development programs. The company operates primarily from its San Francisco headquarters and maintains a presence in Boston, reflecting its national investment scope. It runs initiatives to discover and incubate breakthrough science through internal programs designed to accelerate translational work and product progress. Overall, 5AM Ventures aims to help promising healthcare and life science companies grow from concept to commercialization.

Dementia Discovery Fund is a venture capital organization focused on dementia therapeutics and enabling technologies. Managed by SV Health Investors, it operates as a family of specialized funds that invests exclusively in companies developing novel dementia treatments or the tools that advance them. With offices in London and Boston, it leverages a global network of venture partners, scientists, and strategic collaborators to identify opportunities, form new biotech ventures, and support early-stage development. The organization pursues a dual mandate of delivering measurable patient impact and generating financial returns, supported by a diverse set of investors including pharmaceutical companies, healthcare organizations, and philanthropic partners, all aimed at accelerating progress toward effective therapies for Alzheimer’s disease and related conditions.